Yestar International Holdings Company Limited Board informed the Shareholders and the potential investors that, based on the preliminary review and assessment of the unaudited management accounts of the Group for the year ended 31 December 2015, the Group is expected to record an increase of not less than 80% and 40% in its consolidated net profit of the Group and consolidated net profit attributable to the owners of the parent, respectively, for the year ended 31 December 2015 as compared with that of the year ended 31 December 2014. The substantial increase is mainly attributable to (1) the outstanding performance of In Vitro Diagnostic business with high profit margin; and (2) stable contribution from its imaging products segment.